The trajectory of companies tied to the drug's legacy presents a challenging investment landscape. While the initial surge generated substantial returns , generic alternatives have significantly eroded market https://ragingbookmarks.com/story21636253/copyright-s-flagship-product-and-pharma-a-uncertain-investment